Lumos Pharma, Inc. (LUMO)
| Previous close | 7.33 |
| Open | 7.23 |
| Bid | 7.24 x 1000 |
| Ask | 7.54 x 800 |
| Day's range | 7.23 - 7.54 |
| 52-week range | 6.15 - 11.52 |
| Volume | |
| Avg. volume | 13,627 |
| Market cap | 63.104M |
| Beta (5Y monthly) | 1.02 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Lumos Pharma to Participate in Upcoming Investor Conferences
AUSTIN, Texas, May 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the following upcoming investors conferences: Event:H.C. Wainwright 2022 Global Investment Conference – May 23rd – 26thPresentation:Live presentation May 25th at 4:00 – 4:30 PM EDTWebcast link:Here Event:Jefferies Healthcare Conference – June 8th – 10thPresentation: Live fireside chat
- GlobeNewswire
Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates
--Phase 2 OraGrowtH210 Trial Reached 50% Randomization Milestone – Interim Data from Phase 2 and PK/PD OraGrowtH Trials Anticipated by End of 2022-- --FDA Permits Treatment with LUM-201 Beyond 12 Months and Lifts Partial Clinical Hold-- --Clinical Collaboration Initiated with Massachusetts General Hospital for Evaluation of LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in Phase 2 Pilot Trial-- AUSTIN, Texas, May 10, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stag
- GlobeNewswire
Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial
The IND application for this pilot trial to evaluate oral growth hormone secretagogue, LUM-201, in NAFLD has been approved by the FDAAUSTIN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, initially targeting pediatric growth hormone deficiency, today announced a collaboration with Laura Dichtel, MD of Massachusetts General Hospital to evaluate the orally administered growth hormone (G
